01—Abstract
Summary
Summary of the 8-K filed February 3, 2026. Cited figures are marked; the original filing is the authoritative source.
Viatris Inc. (VTRS) filed this Current Report on Form 8-K under Item 5.02 to disclose a leadership change in its legal function.
The company announced on February 3, 2026 that Brian Roman, Chief Legal Officer, will transition out of that role effective February 9, 2026, and will remain an employee until April 1, 2026 for transitional purposes. In connection with his departure, Mr. Roman is eligible to receive separation payments equal to the sum of his base salary plus target bonus, plus a pro rata bonus for 2026, consistent with severance benefits paid to similarly situated executives. He would also execute a customary release of claims.
The filing does not state any dollar amounts for these payments. The company also announced that Matthew Maletta will join Viatris as Chief Legal Officer on February 9, 2026. The filing describes Mr. Maletta as a seasoned pharmaceutical industry legal professional who served from 2015 to 2025 as Executive Vice President, Chief Legal Officer and Secretary of Endo, Inc.
02—Key points
Key Highlights
- Brian Roman, Chief Legal Officer, will cease serving in that role effective February 9, 2026, and remains an employee until April 1, 2026 for transitional purposes.
- Roman's separation payments equal his base salary plus target bonus and a pro rata 2026 bonus, consistent with severance paid to similarly situated executives, conditioned on a customary release of claims.
- Matthew Maletta will join Viatris as Chief Legal Officer effective February 9, 2026, the same date Roman's role ends.
- Maletta previously served from 2015 to 2025 as Executive Vice President, Chief Legal Officer and Secretary of Endo, Inc.
- The filing discloses no financial results, guidance, or dollar amounts for the separation payments.
03—Questions
Frequently Asked Questions
Who is leaving Viatris's legal leadership role, and when?
Brian Roman, Chief Legal Officer, will cease to serve in that role effective February 9, 2026. He will remain an employee until April 1, 2026 for transitional purposes.
What compensation will the departing Chief Legal Officer receive?
Mr. Roman will be eligible for separation payments equal to his base salary plus target bonus, along with a pro rata bonus for 2026. These are consistent with severance benefits paid to similarly situated executives and are subject to a customary release of claims. The filing does not state specific dollar amounts.
Who is replacing Brian Roman?
Matthew Maletta will join Viatris as Chief Legal Officer on February 9, 2026. The filing describes him as a seasoned pharmaceutical industry legal professional who served as Executive Vice President, Chief Legal Officer and Secretary of Endo, Inc. from 2015 to 2025.
Does this filing indicate any change to Viatris's financial outlook?
No. This Item 5.02 filing covers only executive departure and appointment matters and does not include financial results or guidance.
04—Continue